Cytopenia
21
9
13
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.5%
2 terminated out of 21 trials
66.7%
-19.8% vs benchmark
5%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (21)
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
Early Intervention in High Risk CCUS
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
A Study of Emapalumab for Pediatric Aplastic Anemia
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.
Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing
Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro